Amgen Stock Forecast, Price & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 21.8% and is now trading at $241.94.
View which stocks have been most impacted by COVID-19.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Tuesday, July, 28th. The medical research company reported $4.25 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.81 by $0.44. The medical research company had revenue of $6.21 billion for the quarter, compared to analysts' expectations of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. The business's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.97 EPS.
View Amgen's earnings history.

Amgen announced a quarterly dividend on Thursday, July 23rd. Investors of record on Monday, August 17th will be paid a dividend of $1.60 per share on Tuesday, September 8th. This represents a $6.40 annualized dividend and a dividend yield of 2.65%. The ex-dividend date of this dividend is Friday, August 14th.
View Amgen's dividend history.

Amgen issued an update on its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $15.10-15.75 for the period, compared to the Thomson Reuters consensus estimate of $15.63. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.38 billion.

27 equities research analysts have issued 12 month target prices for Amgen's stock. Their forecasts range from $185.00 to $300.00. On average, they expect Amgen's share price to reach $255.28 in the next year. This suggests a possible upside of 5.5% from the stock's current price.
View analysts' price targets for Amgen.

Amgen saw a increase in short interest in August. As of August 31st, there was short interest totaling 6,200,000 shares, an increase of 41.2% from the August 15th total of 4,390,000 shares. Based on an average daily trading volume, of 2,630,000 shares, the short-interest ratio is currently 2.4 days. Currently, 1.1% of the company's stock are short sold.
View Amgen's Short Interest.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Gilead Sciences (GILD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.34%), BlackRock Inc. (8.32%), FMR LLC (2.92%), Nordea Investment Management AB (1.43%), Bank of New York Mellon Corp (1.14%) and Nuveen Asset Management LLC (0.67%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Advisor Group Holdings Inc., Pzena Investment Management LLC, FMR LLC, Toronto Dominion Bank, LSV Asset Management, Healthcare of Ontario Pension Plan Trust Fund, and AQR Capital Management LLC. Company insiders that have sold Amgen company stock in the last year include David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, BlackRock Inc., Raymond James Financial Services Advisors Inc., Robeco Institutional Asset Management B.V., Marshall Wace North America L.P., Man Group plc, Thrivent Financial for Lutherans, and Sumitomo Mitsui Trust Holdings Inc..
View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $241.94.

Amgen has a market capitalization of $141.70 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]